Skip to content

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Why this mattered

This paper mattered because it turned a newly reported viral genome into a deployable public-health diagnostic before laboratories had routine access to virus isolates. Its central move was practical and conceptual: use sequence similarity to SARS-related coronaviruses, synthetic nucleic-acid controls, and real-time RT-PCR assay design to make detection possible from genomic information alone. That made the response less dependent on culturing the pathogen or waiting for reference material to circulate, shifting outbreak diagnostics toward a genome-first model in which sequence release could be converted almost immediately into laboratory capacity.

The workflow also mattered because it was built for public-health laboratories, not as a bespoke research demonstration. The assays targeted coronavirus genomic regions including the E gene for broad screening and RdRp targets for confirmatory discrimination of 2019-nCoV from SARS-CoV, and the authors validated exclusivity against a large panel of clinical respiratory-virus specimens. In the opening weeks of 2020, that combination made it possible to distinguish SARS-CoV-2 infection from influenza, endemic coronaviruses, and other respiratory illnesses at scale, enabling case confirmation, traveler screening, contact tracing, and epidemiological surveillance before vaccines or therapeutics existed.

Its longer-term significance is that it helped establish the diagnostic infrastructure on which much of the early pandemic response depended. The rapid publication and distribution of primers, probes, protocols, and control material showed how academic groups, public-health laboratories, and international repositories could coordinate around an emerging pathogen in near real time. Subsequent breakthroughs, including genomic surveillance, variant tracking, vaccine trials, and therapeutic studies, all depended on the same prior step: reliable identification of infected individuals. In that sense, the paper was not merely an assay report; it was an early template for pandemic science organized around rapid sequence disclosure, synthetic standards, and distributed diagnostic deployment.

Abstract

Background The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur. Aim We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available. Methods Here we present a validated diagnostic workflow for 2019-nCoV, its design relying on close genetic relatedness of 2019-nCoV with SARS coronavirus, making use of synthetic nucleic acid technology. Results The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses. Control material is made available through European Virus Archive – Global (EVAg), a European Union infrastructure project. Conclusion The present study demonstrates the enormous response capacity achieved through coordination of academic and public laboratories in national and European research networks.

Sources